Compare AVNW & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNW | SLN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United Kingdom |
| Employees | 923 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.0M | 318.4M |
| IPO Year | 2007 | N/A |
| Metric | AVNW | SLN |
|---|---|---|
| Price | $21.34 | $6.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $32.50 | ★ $39.67 |
| AVG Volume (30 Days) | 97.4K | ★ 305.7K |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $453,497,000.00 | $25,830,000.00 |
| Revenue This Year | $5.73 | N/A |
| Revenue Next Year | $6.79 | N/A |
| P/E Ratio | $20.79 | ★ N/A |
| Revenue Growth | 10.72 | ★ 40.39 |
| 52 Week Low | $15.80 | $1.97 |
| 52 Week High | $26.83 | $8.08 |
| Indicator | AVNW | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 46.42 |
| Support Level | $20.77 | $5.99 |
| Resistance Level | $21.83 | $6.59 |
| Average True Range (ATR) | 0.72 | 0.43 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 54.39 | 25.22 |
Aviat Networks Inc provides wireless transport and access networking solutions designed to support telecommunications operators and private network providers situated in various countries. The company offers a range of microwave and millimeter wave radios, network management tools, and services that enable high-capacity, secure, and reliable data transport over wireless networks. Its products serve diverse clients including mobile operators, public safety organizations, utilities, government agencies, and enterprise customers. Aviat generates revenue from the sale of its networking equipment, professional services, and ongoing support contracts. Its operations cover various regions including the Americas, Europe, Asia Pacific, the Middle East, and Africa.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.